Cargando…

Assessment of the Evolution of Cancer Treatment Therapies

Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Arruebo, Manuel, Vilaboa, Nuria, Sáez-Gutierrez, Berta, Lambea, Julio, Tres, Alejandro, Valladares, Mónica, González-Fernández, África
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759197/
https://www.ncbi.nlm.nih.gov/pubmed/24212956
http://dx.doi.org/10.3390/cancers3033279
_version_ 1782477222087491584
author Arruebo, Manuel
Vilaboa, Nuria
Sáez-Gutierrez, Berta
Lambea, Julio
Tres, Alejandro
Valladares, Mónica
González-Fernández, África
author_facet Arruebo, Manuel
Vilaboa, Nuria
Sáez-Gutierrez, Berta
Lambea, Julio
Tres, Alejandro
Valladares, Mónica
González-Fernández, África
author_sort Arruebo, Manuel
collection PubMed
description Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present.
format Online
Article
Text
id pubmed-3759197
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-37591972013-09-04 Assessment of the Evolution of Cancer Treatment Therapies Arruebo, Manuel Vilaboa, Nuria Sáez-Gutierrez, Berta Lambea, Julio Tres, Alejandro Valladares, Mónica González-Fernández, África Cancers (Basel) Review Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present. Molecular Diversity Preservation International (MDPI) 2011-08-12 /pmc/articles/PMC3759197/ /pubmed/24212956 http://dx.doi.org/10.3390/cancers3033279 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Arruebo, Manuel
Vilaboa, Nuria
Sáez-Gutierrez, Berta
Lambea, Julio
Tres, Alejandro
Valladares, Mónica
González-Fernández, África
Assessment of the Evolution of Cancer Treatment Therapies
title Assessment of the Evolution of Cancer Treatment Therapies
title_full Assessment of the Evolution of Cancer Treatment Therapies
title_fullStr Assessment of the Evolution of Cancer Treatment Therapies
title_full_unstemmed Assessment of the Evolution of Cancer Treatment Therapies
title_short Assessment of the Evolution of Cancer Treatment Therapies
title_sort assessment of the evolution of cancer treatment therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759197/
https://www.ncbi.nlm.nih.gov/pubmed/24212956
http://dx.doi.org/10.3390/cancers3033279
work_keys_str_mv AT arruebomanuel assessmentoftheevolutionofcancertreatmenttherapies
AT vilaboanuria assessmentoftheevolutionofcancertreatmenttherapies
AT saezgutierrezberta assessmentoftheevolutionofcancertreatmenttherapies
AT lambeajulio assessmentoftheevolutionofcancertreatmenttherapies
AT tresalejandro assessmentoftheevolutionofcancertreatmenttherapies
AT valladaresmonica assessmentoftheevolutionofcancertreatmenttherapies
AT gonzalezfernandezafrica assessmentoftheevolutionofcancertreatmenttherapies